LIVE MARKET TRACKER :   BSE SENSEX   31599.76      |    NSE NIFTY 9871.50    
GLOBAL MARKETS :  NASDAQ 6370.5898   -0.8765%    |    FSI London 7304.79   +0.05%    |    NIKKEI Japan 20330.19   -0.33%
  USD GBP EUR CAD AUD INR
USD - 0.7452 0.8487 1.2380 1.2677 65.6200
GBP 1.3420 - 1.1386 1.6614 1.7010 88.1017
EUR 1.1788 0.8784 - 1.4593 1.4941 77.3449
CAD 0.8079 0.6024 0.6854 - 1.0244 53.0200
AUD 0.7890 0.5880 0.6695 0.9767 - 51.7650
INR 0.0153 0.0114 0.0129 0.0189 0.0194 -
Indian-Commodity  :  Top News  :  Strides Shasun receives USFDA approval for Cetirizine Softgel Capsules

Strides Shasun receives USFDA approval for Cetirizine Softgel Capsules (24-Jul-2017)

Strides Shasun has received an approval from the United States Food & Drug Administration (USFDA) for Cetirizine Hydrochloride Capsules, 10 mg (Liquid Filled Capsules).  According to IRI data, the US market for Cetirizine Hydrochloride Capsules (Softgel) is approximately $60 million, with only one other generic player.

The product will be manufactured at the company's flagship facility at Bangalore and marketed by Strides Pharma Inc. in the US market. The product is ready for launch immediately and as in the case of OTC products, the market formation takes time and the company expects to have an important market share in approximately six months. This is the first approval for a Softgel product after the recent USFDA inspection at the company's Bangalore facility.

Cetirizine is an antihistamine used to relieve allergy symptoms such as watery eyes, runny nose, itching eyes/nose, sneezing, hives, and itching. It works by blocking a certain natural substance (histamine) that your body makes during an allergic reaction.



Top News Today
Jaiprakash Associates gets nod to raise up to Rs 2,000 crore
(26-Sep-2017)

Jaiprakash Associates gets nod to raise up to Rs 2,000 croreJaiprakash Associates has received its shareholders' approval to raise up to Rs 2,000 crore through sale of securities. The special resolution was approved by the shareholders at the company's annual general......click on news to read complete article.

Panacea Biotec planning to raise Rs 250 crore
(26-Sep-2017)

Panacea Biotec planning to raise Rs 250 crorePanacea Biotec is planning to raise Rs 250 crore by way of issue of equity shares and/or other securities. In this regards, the company is conducting Postal Ballot for obtaining approval of members for......click on news to read complete article.

Novartis India gets nod for Rs 231.15 crore buyback plan
(26-Sep-2017)

Novartis India gets nod for Rs 231.15 crore buyback planNovartis India has received an approval for buyback of up to 34.5 lakh shares, accounting for about 12.26% of the existing paid up capital of the company, for up to Rs 231.15 crore. The company's board......click on news to read complete article.

International Stock News
Asian markets trade mostly lower in early deals on Tuesday
(26-Sep-2017)

Asian markets trade mostly lower in early deals on TuesdayMost of the Asian equity benchmarks are trading down in the early deals on Tuesday, following declines on Wall Street overnight, as the war of words between North Korea and the US escalated. Meanwhile,......click on news to read complete article.

US markets closed lower on North Korea's threat
(26-Sep-2017)

US markets closed lower on North KoreaThe US markets closed lower on Monday, on the back of a fresh flare up in tensions between the US and North Korea and a sharp decline in technology shares. North Korean foreign minister Ri Yong Ho, speaking......click on news to read complete article.

Asian markets trade mostly lower in early deals on Monday
(25-Sep-2017)

Asian markets trade mostly lower in early deals on MondayMost of the Asian equity benchmarks are trading down in the early deals on Monday, following the lackluster cues from Wall Street and concerns about China's economy. Investors digested election results......click on news to read complete article.

 

     
  
Recent Top News News
 
EquityInvestmentCompany ReportsIPO
Disclaimer
By clicking on this page you accept all the terms and conditions framed by us. News made available here are for informational purpose only. While utmost care has been taken in providing the same. We claim no responsibility for its accuracy. Readers of this blog who make their decision based on the information posted here are solely responsible for their actions.